# Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

> **NCT04331626** · PHASE4 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Gemcitabine Injectable Product

## Key facts

- **NCT ID:** NCT04331626
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04
- **Primary completion:** 2022-12
- **Final completion:** 2023-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04331626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04331626, "Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04331626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*